Anzeige
Meldung des Tages: Chinas mineralische Vormachtstellung: Die Verwundbarkeit der Lieferkette, die Washington nicht länger ignorieren kann

MetaVia News

Aktie
WKN:  ISIN:  US64132R5037 US-Symbol:  MTVA
1,54 $
+0,02 $
+1,32%
1,3155 € 23.04.26
Depot/Watchlist
Marktkapitalisierung *
-
Streubesitz
-
KGV
-
Index-Zuordnung
-

MetaVia News

10.04.26 - PR Newswire
MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity
MetaVia Doses the First Patient in Higher-​Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity PR Newswire
26.03.26 - PR Newswire
MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update
MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update PR Newswire
18.03.26 - PR Newswire
MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control
MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-​Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-...
12.03.26 - PR Newswire
MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035
MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035 PR Newswire
04.03.26 - PR Newswire
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum PR Newswire
17.02.26 - PR Newswire
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference PR Newswire
13.02.26 - PR Newswire
MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041
MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041 PR Newswire
04.02.26 - PR Newswire
MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel
MetaVia Announces Positive AI-​Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel PR Newswire
16.01.26 - PR Newswire
MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option
MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option PR Newswire
15.01.26 - PR Newswire
MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering
MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering PR Newswire
05.01.26 - PR Newswire
MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile
MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant ...
29.12.25 - PR Newswire
MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference
MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference PR Newswire
22.12.25 - PR Newswire
MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement
MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement PR Newswire

Newssuche

Videos

newspaper
20.04.26 +0,99%
Technical Trading: GBP Long im Trend
GBP/USD Long Typ: Open End Turbo WKN: VV7A4S Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »